Assembly Biosciences Inc ( (ASMB) ) has released its Q2 earnings. Here is a breakdown of the information Assembly Biosciences Inc presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Assembly Biosciences is a biotechnology company focused on developing innovative therapeutics for serious viral diseases, including herpesvirus, hepatitis B virus (HBV), and hepatitis delta virus (HDV). In its second quarter 2025 financial report, Assembly Biosciences highlighted progress in its clinical trials, including positive topline data for its capsid assembly modulator candidate, ABI-4334, in chronic HBV patients, and interim data for ABI-6250 in HDV. The company is also on track to release proof-of-concept data for its herpes simplex virus candidates, ABI-5366 and ABI-1179, by fall 2025. Financially, Assembly Biosciences reported a net loss of $10.2 million for the quarter, with cash reserves projected to fund operations into mid-2026. Revenue from its collaboration with Gilead increased to $9.6 million, reflecting enhanced research and development activities. Looking ahead, Assembly Biosciences remains focused on advancing its clinical programs and achieving key milestones in the coming months.